Skip to main content

Invitrogen s Revenues Soar, Earnings Decline in Q1

NEW YORK, April 22 (GenomeWeb News) - Invitrogen reported a decrease in earnings for the first quarter, despite a surge in revenues.

 

Revenues climbed almost 40 percent, to $251.3 million, compared to $180.6 million during the same quarter last year. Most of this increase resulted from BioDiscovery products, in particular from products Invitrogen obtained through its acquisitions of Molecular Probes and Pan Vera.

 

Research and development costs were $15.7 million, up from $10.6 million during the same quarter in 2003.

 

Net income for the quarter was $10.5 million, or $.2 per share, down from $16.9 million, or $.34 per share, during the year-ago period. Invitrogen attributed this decrease in earnings to higher amortization of intangibles from acquired businesses and to a $6.8 million charge for the retirement of high cost debt.

 

As of March 31, Invitrogen had cash and investments of $891.3 million.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.